Simple metal stents are usually made of stainless steel and do not have a special drug coating.
They act as scaffolding to support open blood vessels after their expansion with angioplasty.
As the artery heals, tissue grows around the stent, keeping it in place. However, it happens that excessive growth of scar tissue in the arterial lining increases the risk of re-blocking.
Currently, doctors prefer not to deal with such stents. The development of coronary stents significantly improved the results and safety of percutaneous coronary intervention (PCI).
Complications from the use of metal stents are sequalae such as restenosis and the need for revascularization of the targeted lesion. Occurrences of these events have been reduced by the use of drug-eluting stents (DES) drug-eluting stents (DES). Today, a vessel with a conventional stent can be cleared of blockage by application of a special preparation.
However, the delay in the treatment of blood vessels associated with the use of drug stents has been associated with an increase in frequency of late stent thrombosis and the need for prolonged dual anti-platelet therapy (DAT).
Recent innovations in stent technology have made drug-containing stents preferable in most clinical situations, partly because they require a shorter duration of DAT.